Q-omics provides the consensus-scored KIFC3 profile across patient tissues and cancer cell-line models. KIFC3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, KIFC3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, KIFC3 protein abundance shows 32,217 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, HNSC, and LSCC as cancer lineages where KIFC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIFC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIFC3 survival associations across molecular data types. KIFC3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIFC3 RNA expression–survival associations across cancer types. High KIFC3 expression shows unfavorable associations in CESC, ACC, LUSC, COAD, SARC and LGG. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for KIFC3 RNA expression.
This table summarizes KIFC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIFC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIFC3 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, COAD, LIHC and STAD. The HNSC box plot shows higher KIFC3 RNA expression in tumor versus normal tissue (log2 FC = +1.733, t-test p < 0.001).
This table shows molecular features associated with KIFC3 in patient tissues and cancer cell lines. In patient samples, KIFC3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIFC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SKIN.
